Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Breast 1

Conditions

Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Breast Neoplasms 1Advanced Cancers 1

Interventions

Specimen Handling 641pembrolizumab 585Magnetic Resonance Spectroscopy 555Carboplatin 431Cyclophosphamide 381Cisplatin 379Biopsy 376Nivolumab 315Paclitaxel 314Gemcitabine 308Radiotherapy 286Bevacizumab 235Dexamethasone 218fludarabine 206Docetaxel 194durvalumab 189Oxaliplatin 189venetoclax 187Rituximab 175Fluorouracil 175atezolizumab 172Pemetrexed 167Capecitabine 164Radiosurgery 162Doxorubicin 162Radiation 160Ipilimumab 146Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Injections, Subcutaneous × 90 days × Clear all
NCT07603479 2026-05-22

A Phase I Study of JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Jecho Biopharmaceuticals Co., Ltd.

Phase 1 Not yet recruiting
14 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms

NCT07260708 2026-04-21

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Recruiting
42 enrolled

Advanced Cancers

NCT05296798 2026-04-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Hoffmann-La Roche

Phase 3 Active not recruiting
922 enrolled
Breast

Breast Neoplasms

NCT06223516 2026-03-27

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

AbbVie

Phase 1 Active not recruiting
60 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡